Versions Compared

Key

  • This line was added.
  • This line was removed.
  • Formatting was changed.

...

  • Vendors thought that the FDA would hold them accountable for encouraging “off-label use” based on the interpretation of the LOINC code(s) published

  • Vendors may want to limit access to their mappings to paying customers only (or at least know who is downloading LIVD files)

  • Vendors operate internationally, so need to ensure mappings are not just US regulation focused

  • Will IVD vendors provide all LOINCs for an analyte/assay, including all timed, challenge, stimulation/suppression, calculated, ratios, etc.? (even those which the IVD vendor may be unaware on instance basis such as which challenge, stimulant, suppression was used for a lab’s protocol for endocrine tests-glucose, insulin, growth hormone, ACTH, cortisol, etc.?)

    • 300+ glucose tolerance tests. 75 g bolus 1 hour post glucola challenge

    • 2 hr timed urine calcium

    • Serum Calcium/Creatinine ratio; Spot Urine Calcium/Creatinine Ratio

    • Total Volume, specimen source and Ask at Order Entry (AOE) LOINCs

    • “generic interpretations” (not specific for any test result) Immunologist review of results; Coagulation panel interpretation, Service Comment, etc.

    • Calculated tests: eGFR (each formula such as male/female), 24 hr urine calcium rate (utilizing hours of collection and total volume in the calculation),

    • What level of granularity of LOINC is provided?

      • serum glucose

      • serum glucose post challenge

      • serum glucose 1 hour post challenge

      • serum glucose 1 hr post challenge glucose

      • serum glucose 1 hr post 100g glucose challenge

      • serum glucose 1 hr post 100g glucose oral bolus challenge

  • What about test results where there is no LOINC yet or at the granularity/specificity needed?

  • What about Lab Developed Tests (may be from performing lab-such as reference or public health lab, not vendor)

  • What about patient performed/home tests (home covid, pregnancy test, etc.)

  • Need to implement higher level terms, avoidance of many-to-many mapping.

Data aggregation

  • Aggregation using LOINC Axis

    • Allows laboratory data to be aggregated based on the component, property, timing, system, scale, and/or method

    • Does not require additional LIVD data elements to support

  • Method specific to “methodless” data aggregation

    • Identify the “methodless” LOINC code which may be used to aggregate data from method specific laboratory test / LOINC codes

      • Used when the method used to perform the laboratory test does not alter the clinical interpretation of the result

    • May require the addition of a data element to support an “Archetype” LOINC code in order to support a stated definition made by a LOINC author.

      • May be determine computationally negating the need for a data element.

  • LOINC Groups

    • Manually identified groups of LOINC codes for a specific purpose

      • Results from individual LOINC group components may or may not be allowed to be aggregated together

      • “Archetype” code typically assigned by LOINC author indicating that individual LOINC codes in the group may be aggregated.

    • May require additional LIVD data elements to support

  • Clinical aggregation

    • The LOINC Multi-axial hierarchy in addition to LOINC parts may be used to provide useful categorization for data aggregation to be used in the display of results on user interfaces

    • Example - Group all laboratory results that are Chemistry or Chemistry - challenge

      • LP29693-6 | Laboratory |

        • LP343631-0 | Chemistry and Chemistry - challenge

          • 2339-0 | Glucose [Mass/volume] in Blood

    • May or may not require data element(s) in the LIVD file to support if a standardized leaf-level is defined.

  • Custom data aggregation

    • Out-of-scope for this iteration of LIVD as no standardized data element(s) would be definable.

Standards Development Issues

...